Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of British Columbia

$50,000.00

Artificial intelligence-based imaging platform for COVID-19 infection of organoids_x000d_ _x000d_ _x000d_

FY 2020-21

Summary
Repurposing drugs already approved for use in humans is a valid approach to identify SARS-CoV-2 inhibitors with established pharmacological and safety profiles that can be rapidly translated to the clinic for treatment of COVID-19. Based on prior work in which artificial intelligence (AI)-based image analysis was able to detect changes to the endoplasmic reticulum of Zika virus infected cells, we will now apply AI-based image analysis to detect alterations to the endoplasmic reticulum, autophagosomes and other cellular organelles due to SARS-CoV-2 in order to identify inhibitory drug candidates from repurposing compound libraries. Initially, lung epithelial Calu-3 cells will be infected with SARS-CoV-2 in the containment level 3 (CL3) FINDER facility in the Life Sciences Institute at UBC and use AI to identify biosignatures associated with SARS-CoV-2 infection. We will then screen a repurposing library of ~3,000 inhibitors to identify those best able to inhibit SARS-CoV-2 infection. We will subsequently establish a secondary screen of kidney, brain and lung airway organoids, available through our industry partner STEMCELL Technologies Inc. to identify the best and most promising SARS-CoV-2 inhibitors. We will evaluate the new lead compounds for synergistic effect with other drug candidates. This grant will support the development of a state-of-the-art AI image analysis to enhance classification of SARS-CoV-2 infection of cells and organoids and provide improved, quantitative approaches to assess anti-SARS-CoV-2 drug efficacy. Development of AI-based image analysis approaches will support development of novel therapeutics for immediate support against the current COVID-19 crisis and also develop novel approaches to image multiple and varied tissue organoids for application to various disease models.
Program
Alliance Grants
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
553515-2020
Name nom
Nabi, Ivan
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
2800
Research subject group en
Artificial intelligence
Research subject group fr
Intelligence artificielle
Research subject en
Artificial intelligence (computer vision, use2603)
Research subject fr
Intelligence artificielle (vision artificielle, utiliser 2603)
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Artificial intelligence-based imaging platform for COVID-19 infection of organoids_x000d_ _x000d_ _x000d_
Keyword
NSERC
Application summary
Repurposing drugs already approved for use in humans is a valid approach to identify SARS-CoV-2 inhibitors with established pharmacological and safety profiles that can be rapidly translated to the clinic for treatment of COVID-19. Based on prior work in which artificial intelligence (AI)-based image analysis was able to detect changes to the endoplasmic reticulum of Zika virus infected cells, we will now apply AI-based image analysis to detect alterations to the endoplasmic reticulum, autophagosomes and other cellular organelles due to SARS-CoV-2 in order to identify inhibitory drug candidates from repurposing compound libraries. Initially, lung epithelial Calu-3 cells will be infected with SARS-CoV-2 in the containment level 3 (CL3) FINDER facility in the Life Sciences Institute at UBC and use AI to identify biosignatures associated with SARS-CoV-2 infection. We will then screen a repurposing library of ~3,000 inhibitors to identify those best able to inhibit SARS-CoV-2 infection. We will subsequently establish a secondary screen of kidney, brain and lung airway organoids, available through our industry partner STEMCELL Technologies Inc. to identify the best and most promising SARS-CoV-2 inhibitors. We will evaluate the new lead compounds for synergistic effect with other drug candidates. This grant will support the development of a state-of-the-art AI image analysis to enhance classification of SARS-CoV-2 infection of cells and organoids and provide improved, quantitative approaches to assess anti-SARS-CoV-2 drug efficacy. Development of AI-based image analysis approaches will support development of novel therapeutics for immediate support against the current COVID-19 crisis and also develop novel approaches to image multiple and varied tissue organoids for application to various disease models.
University of British Columbia - $50,000 Grant (2020-… | Canada Spends